RxDoctor Payments Data

Alan Ghassan, MD

Internal Medicine · Farmington Hills, MINPI 1760450811

Payments from drug & device makers

$1,657in general payments, 2019–2025

Across 72 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$520
  • Novo Nordisk$380
  • Shield Therapeutics Inc$187
  • Exact Sciences$176
  • GSK$67
  • Novartis$61
  • plus $265 from 10 others

What the payments were for

  • Food & beverage$1,657100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,657 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$259,750
Medicare patients
393
Services billed
2,856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban165$168,798
OzempicSemaglutide100$123,507
JardianceEmpagliflozin77$68,359
JanuviaSitagliptin Phosphate57$60,994
RybelsusSemaglutide44$50,742
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$36,469
XareltoRivaroxaban23$29,081
EntrestoSacubitril/Valsartan21$23,752
TrulicityDulaglutide24$22,584
Tresiba Flextouch U-200Insulin Degludec16$17,136
JanumetSitagliptin Phos/Metformin Hcl11$16,913
LinzessLinaclotide23$11,939
MounjaroTirzepatide11$11,275
Breo ElliptaFluticasone/Vilanterol23$8,770
Levemir FlexpenInsulin Detemir43$8,280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$380$174,249144 claims
PfizerEliquis$520$168,798165 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$67$51,86796 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$35$36,25349 claims
NovartisEntresto$61$23,75221 claims
AstraZenecaSymbicort$53$5,04822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →